• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 0
      ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC - 8 hour(s) ago

      The FDA’s ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC. Read more below: https://t.co/Veze1cdweY

    • Mashup Score: 0
      Durvalumab Plus BCG Boosts DFS in Non–Muscle-Invasive Bladder Cancer - 1 day(s) ago

      Durvalumab added to BCG induction and maintenance improved disease-free survival vs BCG alone in high-risk non–muscle-invasive bladder cancer.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        Durvalumab plus BCG induction/maintenance improved DFS vs BCG alone in NMIBC. Read more below. #oncology #bladdercancer #news #nursing https://t.co/82X9OFldvf

    • Mashup Score: 0
      Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer - 2 day(s) ago

      Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        The addition of panitumumab to neoadjuvant chemo improved outcomes for patients with locally advanced colon cancer. Read more below. #coloncancer #GIcancer #oncology #nurse https://t.co/B2JBmjPhlc

    • Mashup Score: 0
      Pembrolizumab Combo Improves PFS in Platinum-Resistant Ovarian Cancer - 3 day(s) ago

      KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        Pembrolizumab plus paclitaxel with or without bevacizumab improvied PFS in platinum-resistant ovarian cancer. Read more below. #ovariancancer #gyncSM #womenshealth #oncology #nurse https://t.co/TAMUR61T13

    • Mashup Score: 1
      Best Practices in Managing Talquetamab-Associated AEs in Myeloma - 3 day(s) ago

      A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        🎥 Samantha Shenoy, MSN, NP, worked with providers at her institution and beyond to compile best practices on AE management for patients with multiple myeloma on talquetamab. #oncology #nurse #myeloma #interdisciplinarycare https://t.co/IOytiGIsTn

    • Mashup Score: 0
      Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma - 4 day(s) ago

      CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        CAR T-cell therapy CT0596 showed early efficacy and safety signs in patients with relapsed/refractory multiple myeloma. Read more below. #MMsm #myeloma #hematology #oncology #nurse https://t.co/m9XQvM3l2N

    • Mashup Score: 1
      Ribociclib Combo Produces Similar pCR to Chemo in HR+ Breast Cancer - 6 day(s) ago

      Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        Ribociclib plus endocrine therapy produced similar pCR rates to standard chemotherapy in HR-positive, HER2-negative breast cancer. Read more below. #BCsm #breastcancer #oncology #nurse https://t.co/Tz2UGFzbaJ

    • Mashup Score: 0
      First-line Disitamab Vedotin/Toripalimab Ups Survival in HER2+ mUC - 7 day(s) ago

      Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        Disitamab vedotin plus toripalimab increased PFS and OS in the first line of therapy for patients with HER2-positive metastatic urothelial cancer. Read more below. #bladdercancer #urothelialcancer #oncology #nurse https://t.co/6oaVrJZN5Q

    • Mashup Score: 0
      How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC - 8 day(s) ago

      The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        A nurse practitioner at @UCSFHospitals explained some of the factors that should be considered when selecting a frontline CDK4/6 inhibitor for HR+ breast cancer. Read more below. #BCsm #oncology #nursing https://t.co/guH4EYtwx4

    • Mashup Score: 0
      Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma - 8 day(s) ago

      Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.

      Source: www.oncnursingnews.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	OncNursingNews
        OncNursingNews

        The combination of ibrutinib and nivolumab showed efficacy and tolerability in patients with relapsed/refractory CNS lymphoma. Read more below. #oncology #lymphoma #nurse #nursing https://t.co/TzP1QaAP0V

    Load More

    Oncology Nursing News

    @OncNursingNews

    Your online destination for Oncology Nursing news, clinical insights, and resources.

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings